Hester Biosciences Limited (HESTERBIO) Fair Value & Analysis
Healthcare · IN · Market cap ₹18.0B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated yesterday
Share price +12.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1,241 – ₹2,208 · fair‑value band ₹767.07 – ₹1,740 · the ₹2,167 price screens above the ₹1,129 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Hester Biosciences Limited (HESTERBIO) currently trades at ₹2,167, while our model-based Fair Value estimate is ₹1,129 — implying the stock looks roughly 47.9% overvalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Hester Biosciences Limited generated revenue of ₹3.3B at a net margin of 16.7%. Revenue grew 40.3% year over year. It earns a return on equity of 16.6%. Net debt stands at ₹1.9B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India and internationally. It operates through two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutics, nutritional supplements, and specialised formulations to enhance animal wellness and productivity. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Hester Biosciences Limited reported revenue of ₹3.3B in FY2026 versus ₹2.4B in FY2022, a compound +9.1%/yr. Reported net income was ₹556M in FY2026, compounding +9.1%/yr from FY2022.
Is HESTERBIO fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Hester Biosciences Limited (HESTERBIO) undervalued?
What is the fair value of HESTERBIO?
What is the quality score of HESTERBIO?
What is the revenue of Hester Biosciences Limited (HESTERBIO)?
What is the net profit margin of HESTERBIO?
Does Hester Biosciences Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.